- A phase 1b/2a trial evaluated
once- and bi-weekly GZR18, a novel GLP-1 analog, in Chinese
subjects with obesity/overweight
- Pre-clinical studies evaluated the molecular and
pharmacological properties of GZR4, an investigational once-weekly
insulin analog
- Pre-clinical studies evaluated and characterized an
ultra-long-acting basal insulin, GZR33, and its premixed
formulation GZR101
BRIDGEWATER, N.J., June 18, 2024 /PRNewswire/ -- Gan & Lee
Pharmaceuticals (Shanghai Stock Exchange: 603087) announced today
the presentation of three abstracts featuring their investigational
products at the American Diabetes Association's
(ADA's[1]) 84th Scientific Sessions. The
meeting will be held in-person and virtually from June 21-24, 2024, in Orlando, Florida .
All abstracts will be published on the journal
Diabetes® website. Data from the selected studies
will be presented live on June 22,
from 12:30-1:30 PM EDT in the Poster
Hall.
The above abstracts and presentations represent the data that
will be showcased or published by Gan & Lee. This press release
includes forward-looking statements regarding investigational
products currently in development by Gan & Lee. It is important
to note that there are risks associated with drug development, and
there is no guarantee that future studies will produce results
consistent with those presented at the ADA's 84th Scientific
Sessions.
References:
[1]. ADA's 84th Scientific Sessions.
https://professional.diabetes.org/scientific-sessions
[2]. Zhang M, Zhang Y, Peng X, et al. GZR18, a novel
long-acting GLP-1 analog, demonstrated positive in vitro and in
vivo pharmacokinetic and pharmacodynamic characteristics in animal
models. Eur J Pharmacol. 2022;928:175107.
doi:10.1016/j.ejphar.2022.175107
About Gan & Lee
Gan & Lee Pharmaceuticals developed the first Chinese
domestic insulin analog. Currently, Gan & Lee has six core
insulin products, including five insulin analog varieties:
long-acting glargine injection (Basalin®), fast-acting
lispro injection (Prandilin™), fast-acting aspart
injection (Rapilin®), mixed protamine zinc lispro
injection (25R) (Prandilin™25), aspart 30 injection
(Rapilin®30), and one human insulin injection - mixed
protamine human insulin injection (30R)
(Similin®30). The company has two approved
medical devices in China,
namely reusable insulin injection
pen (GanleePen), and disposable pen needle
(GanleeFine®).
In China's second Volume Based
Procurement (VBP) in 2024, Gan & Lee Pharmaceuticals ranked
second overall and first among domestic companies in terms of
procurement demand for insulin analogs. The company is also making
strides in international markets, with the disposable pen needle
(GanleeFine®) approved by the US Food and Drug
Administration (FDA) in 2020 and received GMP inspection approval
from the European Medicines Agency (EMA) in 2024. These
achievements significantly boost Gan & Lee's competitiveness in
both international and domestic markets.
In the future, Gan & Lee will strive for comprehensive
coverage in diabetes treatment. Moving forward with its mission to
become a world-class pharmaceutical company, Gan & Lee will
also actively develop new chemical entities and biological drugs,
focusing on treatments for metabolic diseases, cardiovascular
diseases, and other therapeutic areas.
Further Information
BPRD@ganlee.com(Media)
BD@ganlee.com(Business Development)
Photo - https://mma.prnewswire.com/media/2440424/image_1.jpg
Photo - https://mma.prnewswire.com/media/2440425/image_2.jpg
Logo -
https://mma.prnewswire.com/media/2439708/Gan_Lee_Pharmaceuticals_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/gan--lee-pharmaceuticals-to-present-groundbreaking-data-on-three-innovative-products-at-the-american-diabetes-associations-84th-scientific-sessions-302174998.html